Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Genentech Inc
Genentech Inc_20100107
Genentech Inc_20100114
Genentech Inc_20100128
Genentech Inc_20131212
Genentech Inc_20100121

Genentech Inc patents


Recent patent applications related to Genentech Inc. Genentech Inc is listed as an Agent/Assignee. Note: Genentech Inc may have other listings under different names/spellings. We're not affiliated with Genentech Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Genentech Inc-related inventors


Fgfr1 agonists and methods of use

The invention provides nucleic acid molecules encoding anti-fibroblast growth factor receptor-1 (FGFR1) antibodies and vectors and host cells comprising the nucleic acid molecules.... Genentech Inc

Humanized anti-factor d antibodies and uses thereof

The invention relates to anti-Factor D antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their production and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies... Genentech Inc

Anti-her2 antibodies and methods of use

The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.... Genentech Inc

Anti-wall teichoic antibodies and conjugates

The invention provides anti-wall teichoic acid antibodies, antibiotic-linker intermediates, and antibody-antibiotic conjugate compound, and methods of making and using the same.... Genentech Inc

Therapeutic compounds and uses thereof

and salts thereof, wherein: R1-R4 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of BRG1, BRM and/or PB1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of... Genentech Inc

Processes for the preparation of pyrimidinylcyclopentane compounds

wherein R1 is as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.... Genentech Inc

Triazolopyridine compounds and methods of use thereof

Provided are triazolopyridine compounds that are inhibitors of JAK kinase, such as JAK1, compositions containing these compounds and methods for treating diseases mediated by a JAK kinase. In particular, provided are compounds of formula (I), stereoisomers, tautomers, solvates, prodrugs or pharmaceutically acceptable salts thereof, where R1a, R1b, R1c, R2, R3,... Genentech Inc

Integrin beta7 antagonists and methods of treating crohn's disease

Methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including Crohn's disease are provided. Also provided are methods of administering and dosing integrin beta7 antagonists, such as anti-integrin beta7 antibodies. In addition, methods of administrating and dosing such integrin beta7 antagonists to induce remission or to induce and... Genentech Inc

Chimeric fibroblast growth factors with altered receptor specificity

The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for... Genentech Inc

Anti-il-17a and il-17f cross reactive antibody variants and compositions comprising and methods of making and using same

The present application relates to variants of an anti-IL-17A/F antibody, in particular, an glycosylation variant, a charge variant, an acidic variant, a HMWS variant, a reduction-resistant cross-linked variant, as well as compositions comprising the anti-IL-17A/F antibody and variant(s) thereof, methods of making and characterizing, and method of using the compositions... Genentech Inc

Prevention and treatment of complement-associated eye conditions

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.... Genentech Inc

Methods and compositions for preventing norleucine misincorporation into proteins

The present invention relates to methods and compositions for preventing incorporation of norleucine into proteins during recombinant protein production in bacteria. The present invention also provides microorganism host cells and nucleic acid molecules for use with the methods and compositions provided herein.... Genentech Inc

Gene expression markers and treatment of multiple sclerosis

The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.... Genentech Inc

Heteroaryl pyridone and aza-pyrodine compounds

Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and... Genentech Inc

Pyridazine derivatives as rorc modulators

wherein m, A, X, Y, Z, R1, R2, R3, R4 and R5are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.... Genentech Inc

Tricyclic pi3k inhibitor compounds and methods of use

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases... Genentech Inc

Pharmaceutical compositions comprising akt protein kinase inhibitors

The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.... Genentech Inc

Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes

The invention provides methods and compositions for treating locally advanced or metastatic breast cancer and for enhancing immune function in an individual having locally advanced or metastatic breast cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.... Genentech Inc

Pyrazole carboxamide compounds and methods of use

Pyrazole carboxamide compounds of Formula I are provided, with various substituents, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk, and for treating cancer and immune disorders such as inflammation mediated by Btk. Methods of using compounds of Formula I for in vitro, in situ, and... Genentech Inc

Anti-notch2 nrr antibodies

The invention provides anti-Notch antibodies, and in particular, antibodies that bind Notch2 NRR, and methods of using the same.... Genentech Inc

Masked anti-cd3 antibodies and methods of use

The invention provides masked anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.... Genentech Inc

Multivalent and multiepitopic antibodies having agonistic activity and methods of use

Provided herein are tetravalent antigen binding complexes having agonist activity for a cell surface receptor. In some embodiments, the complexes comprise binding specificities for multiple epitopes of the same cell surface receptor. Further provided herein are nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production related thereto.... Genentech Inc

Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use

The present invention relates to bispecific antibodies that bind to transferrin receptor and BACE1 and methods of using the same.... Genentech Inc

Pyridazine derivatives as rorc modulators

wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.... Genentech Inc

Anti-cll-1 antibodies and immunoconjugates

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

Anti-cll-1 antibodies and immunoconjugates

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

Mutant smoothened and methods of using the same

The emergence of mutations in tyrosine kinases following treatment of cancer patients with molecular-targeted therapy represents a major mechanism of acquired drug resistance. Here, mutations in the serpentine receptor, Smoothened (SMO) are described, which result in resistance to a Hedgehog (Hh) pathway inhibitor, such as in medulloblastoma. Amino acid substitutions... Genentech Inc

Therapeutic compounds and uses thereof

wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of... Genentech Inc

Therapeutic and diagnostic methods for cancer

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness... Genentech Inc

Pertuzumab variants and evaluation thereof

The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated... Genentech Inc

Pertuzumab variants and evaluation thereof

The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated... Genentech Inc

Pertuzumab variants and evaluation thereof

The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated... Genentech Inc

Anti-factor b antibodies and their uses

The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of factor B antagonists.... Genentech Inc

Pyridyl inhibitors of hedgehog signalling

wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.... Genentech Inc

Therapeutic and diagnostic methods for cancer

The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, non-small cell lung cancer (NSCLC). The invention provides methods of treating NSCLC, methods of determining whether a patient suffering from NSCLC is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting... Genentech Inc

02/01/18 / #20180030434

Methods of identifying bacteria comprising binding polypeptides

The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. The invention also provides methods of identifying binding polypeptides with improved expression. The invention also provides engineered bacteria suitable for use in the methods of the... Genentech Inc

01/25/18 / #20180021431

Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.... Genentech Inc

01/25/18 / #20180021450

Anti-staphylococcus aureus antibody rifamycin conjugates and uses thereof

The invention provides anti-Staphylococcus aureus antibody rifamycin antibiotic conjugates and methods of using same.... Genentech Inc

01/25/18 / #20180022707

Therapeutic compounds and uses thereof

The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Genentech Inc

01/25/18 / #20180022727

Therapeutic compounds and uses thereof

The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Genentech Inc

01/25/18 / #20180022809

Anti-pd-l1 antibodies and diagnostic uses thereof

The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.... Genentech Inc

01/25/18 / #20180022813

Antigen binding complex having agonistic activity and methods of use

Provided herein are antigen binding polypeptides and complexes thereof having agonist activity. Also provided are methods for screening for complexes or polypeptides having agonist activity, enhancing the agonist activity of a polypeptide, and for agonizing a cell surface receptor using the complexes and polypeptide described herein.... Genentech Inc

01/18/18 / #20180015177

Anti-ly6e antibodies and immunoconjugates and methods of use

The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.... Genentech Inc

01/18/18 / #20180015179

Anti-cd79b antibodies and immunoconjugates

The invention provides anti-CD79b antibodies and immunoconjugates and methods of using the same.... Genentech Inc

01/18/18 / #20180016325

Anti-wall teichoic antibodies and conjugates

The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.... Genentech Inc

01/11/18 / #20180009735

Therapeutic compounds and uses thereof

and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.... Genentech Inc

01/11/18 / #20180009805

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such... Genentech Inc

01/11/18 / #20180009894

Anti-cll-1 antibodies and immunoconjugates

The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

01/04/18 / #20180000833

Serine/threonine kinase inhibitors

Compounds having the formula I wherein R1, X1, X2, X3 and X4 as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.... Genentech Inc

01/04/18 / #20180000962

Cysteine engineered antibodies and conjugates

where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.... Genentech Inc

01/04/18 / #20180000964

Blood brain barrier receptor antibodies and methods of use

The present invention relates to antibodies that bind to receptors expressed on the blood brain barrier and methods of using the same.... Genentech Inc

01/04/18 / #20180002344

Heteroaryl estrogen receptor modulators and uses thereof

stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I, II, and III compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents,... Genentech Inc

01/04/18 / #20180002433

Anti-transferrin receptor antibodies and methods of use

The present invention relates to anti-transferrin receptor antibodies and methods of their use.... Genentech Inc

12/28/17 / #20170368039

Novel compounds and compositions for the inhibition of nampt

The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:... Genentech Inc

12/28/17 / #20170369510

Tricyclic dlk inhibitors and uses thereof

wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said... Genentech Inc

12/28/17 / #20170369559
12/28/17 / #20170369564

Anti-vegf antibodies

Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.... Genentech Inc

12/28/17 / #20170369869

Expression and secretion system

The invention provides an expression and secretion system, and methods of using the same, for the expression and secretion of one fusion protein in prokaryotic cells and a second fusion protein in eukaryotic cells. Also provided herein are nucleic acid molecules, vectors and host cells comprising such vectors and nucleic... Genentech Inc

12/28/17 / #20170369885

Treatment of th17 mediated inflammatory diseases

The present invention provides methods and means to reduce inflammation associated with IRF-4, AP-1 and TH17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions.... Genentech Inc

12/28/17 / #20170370906

Bioanalytical analysis of site-specific antibody drug conjugates

Methods to rapidly and accurately detect, characterize, measure, and quantify site-specific antibody drug conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.... Genentech Inc

12/21/17 / #20170360928

Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy

The invention provides a method for more effective treatment of patients susceptible to or diagnosed with tumors overexpressing EGFR, as determined by a gene amplification assay, with an EGFR antagonist. Such method comprises administering a cancer-treating dose of the EGFR antagonist, preferably in addition to chemotherapeutic agents, to a subject... Genentech Inc

12/21/17 / #20170362228

Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating... Genentech Inc

12/21/17 / #20170362318

Compositions and methods for the treatment of tumor hematopoietic origin

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.... Genentech Inc

12/21/17 / #20170362339

Antibodies against bace1 and use thereof for neural disease immunotherapy

The invention provides antagonistic antibodies to BACE1 and methods of using the same for the treatment of neurological disease and disorders.... Genentech Inc

12/14/17 / #20170355725
Patent Packs
12/07/17 / #20170348310

Serine/threonine kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in... Genentech Inc

12/07/17 / #20170348422

Silvestrol antibody-drug conjugates and methods of use

The invention relates generally to a silvestrol molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody conjugated by a linker to one or more silvestrol drug moieties and methods of treatment.... Genentech Inc

12/07/17 / #20170349573

Hedgehog antagonists having zinc binding moieties

The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.... Genentech Inc

12/07/17 / #20170349639

Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders

The present invention provides for chimeric Wnt antagonists comprising a Frz domain component derived from a Frizzled protein, a secreted Frizzled related protein or Ror protein and an Fc immunoglobulin component, and their use in the treatment and diagnostic detection of cellular Wnt signaling and Wnt-mediated disorders, including cancer.... Genentech Inc

12/07/17 / #20170349664

Methods for treating progressive multiple sclerosis

The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.... Genentech Inc

11/30/17 / #20170339928

Animal model for nephropathy and agents for treating the same

A non-human transgenic animal expressing ApoL1 is provided as well as a method for generating the same. Also provided is a method for identifying an agent capable of reducing the progression of an ApoL1 mediated nephropathy. Furthermore, an isolated antibody is provided which binds to the human variants of ApoL1.... Genentech Inc

11/30/17 / #20170340604

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and... Genentech Inc

11/30/17 / #20170340605

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods... Genentech Inc

11/30/17 / #20170342067

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods... Genentech Inc

11/30/17 / #20170342163

Anti-htra1 antibodies and methods of use

The invention provides anti-HtrA1 antibodies and methods of using the same.... Genentech Inc

11/30/17 / #20170342488

Methods of using fgf19 modulators

Provided herein are methods of using FGF19 modulators and/or bile acid metabolism biomarkers.... Genentech Inc

11/23/17 / #20170333406

Therapeutic compounds and uses thereof

and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II)... Genentech Inc

11/23/17 / #20170334883

Therapeutic compounds and uses thereof

wherein R1, R3-R6, X, and each Re have any of the values defined in the specification. Also included are novel compounds of formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.... Genentech Inc

11/23/17 / #20170334985

Anti-il-13/il-17 bispecific antibodies and uses thereof

The invention provides anti-IL-13/IL-17 bispecific antibodies, in particular, anti-IL13/IL17 AA, AF and FF antibodies and methods of using the same, including without limitation, methods of using the anti-IL-13/IL-17 bispecific antibodies for treating moderate to severe asthma and/or eosinophilic asthma.... Genentech Inc

11/16/17 / #20170326248

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

Patent Packs
11/16/17 / #20170327574

Methods of treating liver conditions using notch2 antagonists

Methods and compositions for the treatment of liver conditions are provided, such methods and compositions comprising Notch2 antagonists, e.g., anti-Notch2 antibodies. Liver conditions include, but are not limited to, chronic liver disease.... Genentech Inc

11/09/17 / #20170319688

Anti-rspo3 antibodies and methods of use

Provided herein are anti-RSPO3 antibodies and methods of using the same.... Genentech Inc

11/09/17 / #20170320871

Tetrahydroisoquinoline estrogen receptor modulators and uses thereof

and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituent and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating... Genentech Inc

11/09/17 / #20170320926

Il-22 polypeptides and il-22 fc fusion proteins and methods of use

The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to IL-22 receptor associated reagents and methods of use thereof.... Genentech Inc

11/09/17 / #20170320937

Anti-influenza b virus hemagglutinin antibodies and methods of use

The present invention provides anti-influenza B virus hemagglutinin antibodies, compositions comprising anti-influenza B virus hemagglutinin antibodies, and methods of using the same.... Genentech Inc

11/09/17 / #20170320940

Anti-alpha-synuclein antibodies and methods of use

The present invention relates to anti-alpha-synuclein (anti-α-synuclein) antibodies and methods of using the same.... Genentech Inc

11/09/17 / #20170321187

Biologically active c-terminal arginine-containing peptides

The present invention concerns the separation, identification and characterization of active peptide fragments from peptones.... Genentech Inc

11/02/17 / #20170312252

Pyrrolidine amide compounds as histone demethylase inhibitors

The present invention relates to compounds useful as inhibitors of one or more histone demethylses, such as KDM5. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.... Genentech Inc

11/02/17 / #20170312292

Therapeutic compounds and uses thereof

and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of... Genentech Inc

11/02/17 / #20170313704

Process for making tricyclic lactam compounds

Processes are described for the preparation of tricyclic lactam compound of Formula (I), having the structure and intermediates useful for the preparation of (I).... Genentech Inc

11/02/17 / #20170313780

Prevention of disulfide bond reduction during recombinant production of polypeptides

The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.... Genentech Inc

11/02/17 / #20170315132

Multiplexed total antibody and antibody-conjugated drug quantification assay

Methods are disclosed to detect, characterize, measure, and quantify human and humanized antibodies, and their conjugates, that may be present in pre-clinical animal biological samples, or human biological samples, including plasma/serum and tissue samples.... Genentech Inc

10/26/17 / #20170304438

Methods of using anti-cd79b immunoconjugates

Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.... Genentech Inc

10/26/17 / #20170306040

Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate

The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD22 antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD22 antibody-drug conjugate.... Genentech Inc

10/26/17 / #20170306418

Therapeutic, diagnostic, and prognostic methods for cancer

The invention provides methods and compositions to detect expression of one or more biornarkers, including FGFR3, TP53, and/or EGFR, for treating, diagnosing, and providing a prognosis for cancer, e.g., bladder cancer. The invention also provides kits and articles of manufacture for use in the methods.... Genentech Inc

10/26/17 / #20170306419

Diagnostic markers

The present invention provides methods of predicting response to a cancer therapy based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of predicting response to an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.... Genentech Inc

10/19/17 / #20170296550

Aryl sultam derivatives as rorc modulators

wherein m, n, p, q, Ar, A, W, X1, X2, X3, X4, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.... Genentech Inc

10/12/17 / #20170290883

Vascular disruption agents and uses thereof

Uses of Apo2L/TRAIL polypeptides and death receptor agonist antibodies to disrupt tumor associated vasculature are provided. Methods of treating cancer in mammals, kits, and articles of manufacture are also provided.... Genentech Inc

10/12/17 / #20170290913

Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.... Genentech Inc

10/12/17 / #20170290920

Anti-cd22 antibodies and immunoconjugates

The invention provides anti-CD22 antibodies and immunoconjugates and methods of using the same.... Genentech Inc

10/12/17 / #20170291940

Il-17a/f heterologous polypeptides and therapeutic uses thereof

The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present... Genentech Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Genentech Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Genentech Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###